✦ LIBER ✦

AMG 386 combined with either pegylated liposomal doxorubicin or topotecan in patients with advanced ovarian cancer: Results from a phase Ib study

✍ Scribed by R. Wenham; R. Schilder; C. Pippitt; S. Wong; S. Ananda; S. Scudder; R. Melara; N. Nanayakkara; H. Adewoye; I. Vergote

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pegylated liposomal doxorubicin (CAELYX®

✍ Jalid Sehouli; O. Camara; M. Schmidt; S. Mahner; G. Seipelt; B. Otremba; B. Schm 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 286 KB

Pegylated liposomal doxorubicin in combi

✍ Alexandros Ardavanis; Dimitris Mavroudis; Kostas Kalbakis; Nikolaos Malamos; Kos 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 292 KB

Phase 3 randomised study of canfosfamide

✍ I. Vergote; N. Finkler; J. del Campo; A. Lohr; J. Hunter; D. Matei; J. Kavanagh; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 317 KB

Patient-reported outcomes in relapsed ov

✍ Carolyn N. Krasner; Andres Poveda; Thomas J. Herzog; Jan B. Vermorken; Stanley B 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 553 KB

8051 Final results of a phase I study of

✍ Lacave, A.J.; Crespo, G.; Fonseca, P.J.; Villanueva, N.; Berros, J.P.; Vieitez, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

512 POSTER Interim results from a Phase

✍ P. Antonella; C. Sessa; A. Delmonte; G. Del Conte; A. Fasolo; E. Dall'O'; F. Zan 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 76 KB